Intravenous excretory urography using Optiray in office urology.
Experiences with the nonionic contrast medium Optiray 300 were analyzed in 120 consecutive patients who underwent intravenous urography. Allergic diathesis was recorded prior to the examination in 12.5% of the patients, pretreatment was given in only 3 cases. The clinical safety of Optiray was outstanding, no adverse reactions were noted. Diagnostic quality of the radiographs was excellent in 78% and good in 22% of the cases. Optiray is considered to be a safe and effective contrast agent for use in intravenous excretory urography.
Koncz
P M
PM
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003287:Contrast Media / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007674:Kidney Diseases / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D012189:Retrospective Studies; D014283:Triiodobenzoic Acids / Q000008:administration & dosage*; D014567:Urography
D003287:Contrast Media; D014283:Triiodobenzoic Acids; C054871:ioversol